Stocktoria

SIGA TECHNOLOGIES INC SIGA

Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
16.02
Altman Z″ — distress risk · safe
185.2%
Dividend payout · at-risk

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$94.6M$23.3M$198.8M
2024$138.7M$59.2M$215.8M
2023$139.9M$68.1M$196.9M
2022$110.8M$33.9M$170.2M
2021$133.7M$69.5M$174.3M
2020$125.0M$56.3M$129.8M

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Marshall Joseph W IIIdirector2026-06-09Disposition7,235$4.39
KEANE JOHN Mdirector2026-06-09Option exercise24,116
KEANE JOHN Mdirector2026-06-09Disposition7,235$4.39
Ford Harold Eugene Jr.director2026-06-09Option exercise24,116
Ford Harold Eugene Jr.director2026-06-09Disposition7,235$4.39
Phillips Holly L.director2026-06-09Option exercise24,116
Phillips Holly L.director2026-06-09Disposition7,235$4.39
Marshall Joseph W IIIdirector2026-06-09Option exercise24,116

Why these scores methodology →

Piotroski F-score: 5/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: 16.02 (safe)

  • Working capital / assets 0.888
  • Retained earnings / assets -0.196
  • EBIT / assets 0.108
  • Equity / liabilities 9.63

Source: SEC EDGAR filings · CIK 0001010086 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.